Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Detroit, Michigan

This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7248
Shown on this page
12
Current sort
Recently updated
Location scope
Detroit, MI
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Detroit, Michigan. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 841–852 of 7,248 matching trials in Detroit, MI.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Completed Phase 1Phase 2 Interventional

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

NCT04626518
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Favezelimab/Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Suspended Not applicable Interventional

The CONFORM Pivotal Trial

NCT05147792
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
CLAAS, WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
Device
Lead sponsor
Conformal Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034
View directory record Official record
Conditions
Ischemic Stroke; Ischemic Attack, Transient
Interventions
Milvexian, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
127
States / cities
Mesa, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Completed Phase 2 Interventional Results available

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05287113
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years to 99 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Recruiting Phase 3 Interventional

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
66
States / cities
Daphne, Alabama • Springdale, Arkansas • Duarte, California + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049
View directory record Official record
Conditions
Crohn Disease
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
77
States / cities
Dothan, Alabama • Chandler, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Completed Not applicable Interventional

SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation

NCT03230747
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Disease
Interventions
Edwards SAPIEN M3 System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Terminated Phase 2 Interventional Results available

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

NCT03108495
View directory record Official record
Conditions
Cervical Carcinoma
Interventions
LN-145, LN-145 + pembrolizumab
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Terminated Phase 3 Interventional Results available

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

NCT05605093
View directory record Official record
Conditions
COVID-19
Interventions
Shionogi Protease Inhibitor (S-217622), placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
103
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Recruiting Not applicable Interventional

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

NCT05172960
View directory record Official record
Conditions
Aortic Stenosis, Severe
Interventions
SAPIEN X4 THV, SAPIEN X4S
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
58
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Completed Phase 2 Interventional

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

NCT06017609
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
JTT-861 Capsules, Placebo Capsules
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Crystal River, Florida • Hialeah, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 9:12 AM EST
Active, not recruiting Not applicable Interventional

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

NCT04228978
View directory record Official record
Conditions
Peripheral Artery Disease, Overweight or Obesity
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Chicago, Illinois • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 9:12 AM EST